Additional Details
-
FAPI PET for Lung Fibrosis
UCLA / Jonsson Comprehensive Cancer CenterLos Angeles CA. 90095View Details -
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
University of ArizonaTucson AZ. 85724View Details -
Transplantation Using Hepatitis C Positive Donors, A Safety Trial
University Health Network Toronto General HospitalToronto ON. M5G 2N2View Details -
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study
Research Institute McGill University Health CenterMontréal QC. H4A3J1View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
BC Children's HospitalVancouver BC. V6H 3N1View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Vanderbilt University Medical CenterNashville TN. 37232View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Children's Hospital of PhiladelphiaPhiladelphia PA. 19104View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
The Hospital for Sick ChildrenToronto ON. M5G 1X8View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Weill Cornell MedicineNew York NY. 10021View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Children's Hospital of Pittsburgh of University of Pittsburgh Medical CenterPittsburgh PA. 15224View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Children's Hospital Los AngelesLos Angeles CA. 90027View Details -
A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Children's Hospital ColoradoAurora CO. 80045View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
UCLA Health Westwood Medical PlazaWestwood CA. 90095View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
National Jewish Health Medical Center ( Site 4015)Denver CO. 80206View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
University of Michigan Hospital ( Site 4001)Ann Arbor MI. 48109View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
Rutgers Robert Wood Johnson Medical School ( Site 4013)New Brunswick NJ. 08901View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
UT Physicians Rheumatology ( Site 4007)Houston TX. 77030View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
St. Joseph's Health Care London ( Site 4701)London ON. N6A 4V2View Details -
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
MedStar Georgetown University Hospital ( Site 4005)Washington DC. 20007View Details